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Objective:    Assess the determinants of medical costs for depressed individuals. 
Method:    Using medical insurance claims for a population of depressed individuals with 
employer provided insurance, we estimated multivariate models of the costs for general medical care, 
exclusive of costs for mental health services, following diagnosis.  Explanatory variables included 
provider choice (psychiatrist or non-physician mental health specialist), treatment choice (medication, 
psychotherapy, or combination treatment); treatment adequacy as defined by APA guidelines; 
characteristics of depression symptoms and severity; and other demographic characteristics.   
Results:  On average, there were increases in the costs for general medical services in the year 
following diagnosis of a depressive disorder.  The increases in general medical costs were slightly higher 
when depressed persons received a treatment for depression when compared to those who did not 
receive a treatment for depression. Among those treated, there was no significant difference between 
those who received an adequate course of treatment when compared with those who did not.  
Significant predictors of high medical costs following diagnosis included choice of a non-psychiatrist as 
the initial provider, high pre-period medical costs, and several measures of severity.   
Conclusions:    Our findings suggest that a diagnosis of depression is associated with increases 
in costs for general medical care.  These increases are more modest when care is initially provided by a 
psychiatrist.  
 
Introduction 
 
Provision of mental health services is sometimes associated with reduction in the need for 
general medical services, a phenomenon known as the medical cost-offset effect (Olfson, Sing and 
Schlesinger 1999; Hankin et al. 1983; Friedman et al. 1995; Holder and Blose 1987; Mumford et al. 
1984; Borus et al. 1985; Pallack et al. 1993; Fiedler and Wright 1989).  Several hypotheses have been 
advanced to explain its existence.  First, many mental disorders appear to cause physical distress that 
may be most effectively addressed by mental health treatments.  Second, specialized mental health care 
can affect the perception and expression of physical illness, reducing the perceived need for non-mental 
health care.  Third, specialized psychiatric care can directly substitute for non-psychiatric medical care 
by providing comfort, support, triage, and direct medical services that might otherwise be offered by 
general medical care providers.  Fourth, specialized mental health care can discourage patients from 
using unnecessary or inappropriate medical services.  Finally, mental health services might encourage or 
facilitate better self-care and fewer risky behaviors, with resulting improvement in health status and 
reduced need for medical services. 
In spite of the intuitive appeal of the hypotheses in favor of the medical cost-offset, evidence for 
extensive offsets has been neither consistent nor conclusive, with several explanations offered.  In some 
cases, the nature of the illness may limit any potential offset.  For example, many physical illnesses are 
associated with high rates of mental disorders.  In these cases, treatment of the mental disorder would 
not be expected to have an extensive effect of use of medical services for the underlying physical illness 
(Holder and Blose 1987; Callahan, Kesterson, and Tierney 1997).  In addition, use of general medical 
services could be stimulated if  
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use of mental health services represents the first contact with medical care.  In other cases, the data and 
methods used may have served to limit the observation of an offset, even when one might exist.  For 
example, many studies examine the effects of mental health treatment generally and not the effect of 
treatment on specific mental disorders.  Mental disorders and their treatments are heterogeneous, and 
cost patterns of patients with different mental disorders vary substantially.  Aggregating all conditions 
and treatments into a single study is likely to result in a loss of significant information. 
More recent analyses of the medical cost-offset have examined the specific case of the 
treatment of depressive disorders (Simon and Katzelnick 1997; Thompson et al. 1998; Katzelnick et al. 
1997; Zhang, Rost, and Fortney 1999).  Depressive disorders are common and associated with high 
costs of treatment and social burden (Kessler et al. 1994; Greenberg et al. 1993), and they are 
frequently associated with costly co-occurring physical illness (Croghan, Crown, and Obenchain 1998; 
Kathol and Petty 1981).  In addition, treatment of depression has significantly changed over the past 12 
years, with new pharmacological and psychotherapeutic options becoming widely available.  The 
effectiveness of these new treatments could increase the likelihood of a medical cost-offset effect.  
Consistent with these observations, studies have shown a small offset for high utilizers of general medical 
services (Katzelnick et al. 1997; Zhang, Rost, and Fortney 1999) and for those who receive high quality 
pharmaceutical care (Thompson et al. 1998). 
The purpose of this paper is to extend prior work on medical cost-offset associated with 
treatment of depressive disorders in several important ways.  First, because treatments and providers 
may vary, we examine the relationship of provider type and the adequacy of treatment on any potential 
offset.  Second, because behavior change with regard to use of general medical services may lag behind 
initiation of treatment for depression, we study medical costs and offsets in the six-month period 
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immediately following the initial diagnosis of depression and again six months later (Simon and 
Katzelnick 1997)).  Although we are unable to document an offset effect, we find significant differences 
in the increases in costs.  Specifically, our results suggest that receiving depression care from non-
psychiatrists is strongly associated with higher use of general medical services and costs.  
 
Methods 
 
The objective of this study is to determine the characteristics of mental health care that predict 
changes in the cost of general medical services following a diagnosis of a depressive disorder.   
Data and Episode Construction 
Study subjects were identified from a subset of the MarketScanâ database (The MedStat 
Group, Ann Arbor, MI), a system of standardized medical and pharmacy insurance claims for about 6 
percent of Americans with employer provider insurance benefits, most under fee-for service or 
discounted fee-for-service/Preferred Provider arrangements.  Only a small number of individuals with 
fully capitated insurance arrangements are missing in the data.  To be included in the study, subjects 
aged 18 to 65 had to have at least one claim with a primary diagnosis of a depressive disorder from a 
mental health specialty provider during the years 1990-1994.  The diagnosis of a depressive disorder 
was identified using the International Classification of Diseases—9th Edition—Clinical Modification 
(ICD-9-CM) codes 296.2x, 296.3x, 300.4, 309.0, 309.1, or 311.x.  A mental health specialty 
provider was defined by provider codes for psychiatrists, psychologists, and counselors—e.g., 
psychiatric social workers, or a facility code indicating a mental health clinic on at least one claim for 
which a depressive disorder was listed.  We excluded subjects whose diagnosis was made in primary 
care because of our greater confidence in claims-based diagnosis made provided from the mental health 
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sector (Rost et al. 1994; Badger et al. 1994).  In keeping with our objective to study cost-offsets 
associated with depressive disorders, we also excluded subjects with any claims history suggesting 
bipolar affective disorder, schizophrenia or other psychosis, and substance abuse.   
In order to study new episodes of treatment, we created 18-month episodes of care for each 
individual included in the final analytic sample.  The index date for each episode was identified by the 
date of the claim with the first diagnostic indicator of depression.  Episodes of care were defined as the 
period beginning six months prior to the index date until 12 months after the index date.  All subjects 
had to be eligible for insurance benefits throughout the entire 18-month episode.  Subjects with evidence 
of mental health care, either psychotherapy or medication treatment (except use of minor tranquilizers) 
during the six months prior to the index date were excluded from further analysis.  We included persons 
who used anxiolytics during this pretreatment period for a number of reasons.  First, anxiolytic use is 
common but sporadic in the population we study.  Second, their use is informative regarding 
complicating psychiatric illness or symptoms that may indicate severity and/or chronicity.  Third, our 
prior research has shown that use is associated with costs, so that while the interpretation of the any 
results may be complex, including these individuals is important to the overall results of our study.  These 
inclusion and exclusion criteria result in a final analytic sample of 5,842 subjects. 
Cost Measures 
For each subject, costs for paid-claims were tabulated for all general medical services, including 
ambulatory care, pharmacy, and hospital services, for each six month period beginning with the pre-
treatment period.  We excluded costs associated with claims for which the primary diagnosis listed 
indicated a mental health problem (ICD-9-CM codes 290-319) and those indicating a mental health 
specialty provider or clinic.   
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After empirically examining several ways to assess cost-offset, we chose the change between 
pre-treatment costs and post-treatment costs because it appeared most responsive and informative, and 
because it has empirical justification in the literature (Pallack et al. 1993; Katzelnick et al. 1997).  
Specifically, we calculate (1) the difference in costs between the six months prior to the index date and 
the immediate six months after the index date, hereafter called the immediate cost differential, and (2) 
the difference between the six months before the index date and the second six-month period following 
the index date, hereafter called the lagged cost differential.  All costs were adjusted for inflation using the 
medical portion of the consumer price index. 
Independent Variables 
In assessing the determinants of changes in costs associated with treatment of depressive 
disorders, we first looked for variables that might be under some degree of control by the patient, 
provider, or system of care, and then controlled for socio-demographic and health status variables.  
Using this framework, the determinants of primary interest measured processes of care and included 
choice of provider, choice of treatment, and the adequacy of treatment.  Providers were classified 
according to whether care was initiated by a psychiatrist or by a non-psychiatrist mental health 
professional (all others).  Treatment choices were medication only, psychotherapy only, or combination 
treatment.  Medication treatment was identified by the presence of one or more pharmacy claims for an 
antidepressant at any time during the post-index period.  Psychotherapy was determined by the 
occurrence of one or more therapeutic procedure codes 90841-90857.  Medication only and 
psychotherapy only treatment were determined by the occurrence of one treatment only.  Combination 
treatment was determined by the occurrence of both an antidepressant prescription and a therapeutic 
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procedure code for psychotherapy at any time during the post-index period.  For combination treatment 
to occur, medication and psychotherapy did not need to occur simultaneously. 
Adequacy of medication and psychotherapy treatments was determined by adherence to the 
recommendations for treatment of major depression by expert panels of the Agency for Health Care 
Policy and Research (AHCPR) and the American Psychiatric Association (APA) (Depression Guideline 
Panel 1993; “Practice Guideline for Major Depressive Disorder in Adults 1993).  In general, these 
guidelines recommend specific lengths of treatment that can be assessed in claims data. In spite of 
expert recommendations, however, measuring the adequacy of psychotherapy treatment proved 
challenging.  Both the AHCPR and APA guidelines recognize that many episodes of major depression 
may spontaneously remit and therefore recommend a period of “watchful waiting.”  In this circumstance, 
the expert panels suggest that as few as two follow-up sessions are appropriate.  In most cases, 
however, a minimum of six sessions is considered consistent with the expert recommendations.  During 
preliminary sensitivity analysis, we examined both the two- and six-session standard and found no 
significant differences associated with changes in medical costs.  For the final models, we therefore used 
two follow-up visits as our measure of adequate care.   
Adherence to medication guidelines was determined by filling four prescriptions for any 
antidepressant during the first six months following the index date.  This measure of the adequacy of 
antidepressant treatment has been used successfully in prior research and shown to be a clinically 
relevant marker (Sood et al. 2000; Melfi et al. 1998).  We considered subjects who received 
combination treatment to have received adequate care if the process of care was consistent with either 
the medication or the psychotherapy measures of adequacy.  These measures resulted in seven mutually 
exclusive categories: (1) adequate antidepressant treatment, (2) adequate psychotherapy, (3) adequate 
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combination therapy, (4) inadequate antidepressant treatment, (5) inadequate psychotherapy, (6) 
inadequate combination therapy, and (7) no treatment, which was always considered inadequate. 
Statistical Analysis 
We used ordinary least squares (OLS) regression to predict the difference between prior period 
and the immediate and lagged post-period costs of general medical services.  In addition to the primary 
variables of interest—i.e., provider choice and adequacy of care—we adjusted the models for age and 
sex, measures of general health status, and type of depression. General health status was assessed by 
the total of major diagnostic categories that appeared in the claims history except those associated with 
mental illness (MDC count).  Severity measures included the specific depression diagnosis identified by 
the ICD-9-CM indicator at the index date and use of anxiolytics at any time during the episode.  We 
also included an indicator for the year of the index date to account for systematic changes in the way 
depressive disorders were treated during the years of the study. 
We used sample selection techniques to account for the possibility of systematic differences 
between subjects who selected a psychiatrist and those who selected a non-psychiatrist for their initial 
mental health care. The explanatory variables used in the first stage probit model of provider choice 
included age, gender, MDC count, a semi-annual time index, use of non-psychiatric in-patient services 
in the pre-index period, number of physician office visits in the pre-index period, total non-psychiatric 
care costs in the pre-index period, and geographic and occupational variables. An Inverse Mills Ratio 
generated from this model was used to control for sample selection bias in the cost-offset models 
(Crown et al. 1998). 
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Results 
 
Of the 5,842 subjects included in the study, 2,873 received the initial diagnosis of a depressive 
disorder by a non-psychiatrist and 2,969 received the initial diagnosis from a psychiatrist.  Table 1 
stratifies the observations by treatment type, treatment adequacy, and initial provider type.  Of the 
2,873 initially treated by non-psychiatrists, 2,108 (73.4 percent) had no indication of follow-up care for 
a depressive disorder.  Of those treated, 600 (78.4 percent) received adequate care, and 165 (21.6 
percent) received inadequate care.  Of the 2,969 persons initially evaluated by psychiatrists, only 194 
(6.5 percent) had no indication of follow up care. The majority of treated patients received 
psychotherapy (1,859, 67.0 percent) or combination treatment (872, 31.4 percent).  In contrast to 
subjects initially evaluated by non-psychiatrists, the overwhelming majority of subjects diagnosed by 
psychiatrists (2,551, 85.9 percenbt) received care that met our criteria for adequacy; this difference in 
adequacy of treatment based on diagnosing provider type is strongly significant (c2= 2486, p<0.001).   
The adequacy of treatment differs with provider type among those subjects that received a 
course of treatment.  For patients diagnosed by psychiatrists and subsequently treated, 92 percent 
received adequate treatment, while 78 percent of patients diagnosed by non-psychiatrists and 
subsequently treated received adequate treatment (c2= 112, p<0.001).  It is interesting to note that 
some persons whose diagnosis appears to have been made by a non-physician mental health specialist 
nevertheless received “medication-only” treatment.  The adequacy of this treatment was not significantly 
different from others whose diagnosis of a depressive disorder first appears on a claim from a non-
physician mental health specialist.  We cannot tell the characteristics of the prescriber—i.e., physician, 
nurse practitioner, etc.—from our data. 
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Table 2 shows the magnitude of the immediate and lagged differences in general medical costs 
according to initial provider, treatment type, and treatment adequacy.  Overall, in the immediate period, 
the difference in medical costs increases between treated subjects and untreated subjects is not 
statistically significant.  In the lagged period, however, the cost increase for treated subjects is $483 ± 
158 higher than the cost increase for untreated subjects, a statistically significant difference [t = 3.06, p< 
0.01] (data not shown).   
The univariate analysis suggests that adequacy of treatment alone does not seem to have a 
substantial effect on cost changes. General medical costs in the immediate period tended to increase for 
those receiving adequate care were higher than for those receiving inadequate care, a statistically 
significant difference [t = 2.16, p<0.05    ].  In the lagged period, general medical costs were not, 
however, significantly different from those in the pre-index period for those receiving adequate care [t = 
0.76, p= 0.45].   
The differences in cost differentials shown in Table 2 may be partially explained by cost 
differences between treated and untreated subjects.  Within the treated subsample, adequacy of 
treatment does not appear to affect changes in medical costs.  Although medical costs increased on 
average following the diagnosis, in both the immediate and lagged periods there is no statistically 
significant difference in the cost increase between subjects whose care was adequate and subjects who 
received care but whose care was inadequate (t = 1.07, p= 0.28, and t = 0.88, p=0.38, respectively).   
In Table 3, we further stratify the sample according to whether or not subjects are observed to 
have an increase or decrease in expenditures for general medical disorders according to provider type 
and treatment adequacy. There are no systematic differences observed for those receiving adequate 
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treatment compared to those who received inadequate treatment, and we do not observe differences in 
the magnitude of increases in medical costs according to provider type. 
Although these univariate statistical tests are useful for investigating differences among various 
types of subjects in our subsamples, the large standard deviations limit the usefulness of the point 
estimates.  We therefore use ordinary least squares regression  to further investigate the factors that 
influence changes in medical costs and present the results in Table 4.  For both time periods, receiving 
the initial diagnosis of depression from a non-psychiatrist is associated with a large and significant 
increase in general medical costs.  After adjusting for the initial provider choice, type and adequacy of 
treatment are not associated with significant increases or decreases in general medical costs.  Correlates 
of significant reductions in costs of general medical services, including gender and high use of various 
medical services in the pre-diagnosis period, predict cost differentials in both the immediate and lagged 
time periods.  Factors associated with increases in general medical costs include age, recurrent major 
depression (lagged period only), use of anxiolytics, and the number of comorbid medical conditions.  
 
Discussion 
 
The purpose of this study is to extend prior work on medical cost-offset by examining the 
effects of choice of initial mental health provider, treatment choice, and the adequacy of treatment, on 
changes in the costs of subsequent general medical services.  Overall, we are unable to document a 
medical cost-offset for the population studied here.  Indeed, the costs of general medical services 
increased slightly for most of those who received a treatment for a depressive disorder.  Among those 
treated, there was no significant difference between those who received adequate treatment and those 
who did not.  With regard to patient characteristics, subjects who appeared to be high utilizers of 
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general medical services in the pre-diagnosis period had a significant medical cost-offset.  These results 
are consistent with recent studies of medical cost-offset in depressed individuals (Katzelnick et al. 1997; 
Zhang, Rost, and Fortney 1999). 
In spite of the absence of a medical cost-offset effect in this study, there are several significant 
findings that suggest choice of provider and treatment play significant roles in the costs of general 
medical services and the adequacy of treatment.  Most importantly, choice of a non-psychiatrist as the 
initial provider was associated with a significant increase in general medical costs for both the immediate 
and lagged periods when compared to the choice of a psychiatrist.  This finding was most consistent for 
those who received inadequate care in the immediate period following diagnosis.  The finding that many 
individuals who received adequate care had increases in general medical costs during the lagged periods 
may be consistent with the return of those patients to the general medical sector following completion of 
psychiatric care. 
The most dramatic finding of this study is the significant difference in the adequacy of treatment 
when initial evaluation and treatment were received from psychiatrists as opposed to non-psychiatrist 
mental health specialists.  Patients receiving initial care from psychiatrists are four times more likely to 
receive an adequate course of treatment, with most of the difference associated with the likelihood of 
receiving any treatment beyond the initial evaluation.  Further study of the reasons for this difference in 
the adequacy of care will be important if we are to understand whether the difference is appropriate or 
whether it is associated with poor clinical outcome.  Many factors, including pathways to care, 
perceptions and expectations of outcome or side effects of medications, the availability and accessibility 
of services, and insurance benefits are all likely to affect the likelihood of receiving treatment and its 
subsequent adequacy. 
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As in any quasi-experimental approach, there are several limitations to this study that must be 
mentioned.  We know, for example, that there are systematic associations between provider choice, 
treatment choice, and adequacy of treatment.  While we are able to adjust for these differences in the 
statistical analysis, other factors that we could not observe in the data may also have had an influence on 
the measurement of medical costs.  Our use of sample selection models should have mitigated any bias 
that such unobserved factors may have introduced, but we cannot be certain of residual effects.  Only 
well-controlled, randomized trials will provide an adequate assessment of these factors.  Second, our 
study is limited to those who received initial diagnosis from a mental health specialist, limiting the 
generalizability of the study.  Although we made this decision in order to have more confidence in the 
diagnosis listed on the insurance claim represented a depressive disorder, most medical care for 
depression is initiated in primary care settings.  Further studies of medical cost-offsets in primary care 
settings will be necessary.  Finally, it is important to note that we applied guidelines for treatment of 
major depression to all forms depressive disorder.  We do not yet know, however, the appropriateness 
of these guidelines in treatment of these disorders, further study is needed to determine their effect on 
outcomes and costs of care. 
Although any medical cost-offset is secondary to the goal of providing high quality treatment to 
those who need it, determination of the existence of an offset and the determinants of changes in medical 
costs that are associated with receipt of mental health treatment are of more than academic interest.  
More than 60 percent of Americans receive employer provided health insurance, many of which 
segregate or “carve-out” the mental health benefit from the benefit for general medical services.  The 
purchasers of this care must understand the economic impact of its contracting and allocation decisions 
between medical and mental health services.  In this regard, it appears that managed mental health care 
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companies that encourage integrated psychiatric services may provide the best value by limiting the 
costs of general medical services.  Whether this choice is also associated with improvements in the 
adequacy of care remains to be determined. 
There are also important policy implications from our study.  Access to mental health treatment 
has improved with the introduction of new treatments, including newer psychiatric medications and 
psychotherapy techniques (Foote and Etheridge 2000).  Our finding that general medical costs increase 
when persons access mental health treatment in the “SSRI era” suggests that, on balance, many 
recipients are now low-utilizers of medical care whose first interaction with the medical care is through 
the mental health system.  The study presented here can not answer questions regarding the 
appropriateness or outcome of that care, but it is important to remember that rising costs for general 
medical care may represent fulfillment of previous unmet medical need (Croghan 2001).  It may also 
mean that the promise of a medical cost-offset, apparently not yet fulfilled, will only be kept by 
treatments that span the domains of physical and mental disorders. 
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Table 1.    Adequacy of Care 
 
Provider 
 Psychiatrist Non-Psychiatrist Total 
Medication Only    
Adequate 28 146 174 
Inadequate 16 76 92 
    
Psychotherapy Only    
Adequate 1,673 289 1,962 
Inadequate 186 78 264 
    
Combination    
Adequate 850 165 1,015 
Inadequate 22 11 33 
    
No Treatment    
Inadequate 194 2,108 2,302 
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Table 2.    Immediate and Lagged Differences in Costs of 
General Medical Servicesa 
 
Provider 
Psychiatrist Non-Psychiatrist 
 Immediate Lagged Immediate Lagged 
Medication Only     
Adequate 2,566 
(3,812) 
 
1,094 
(3,353) 
1,737 
(7,137) 
1,241 
(3,914) 
Inadequate -172 
(1,911) 
 
968 
(2,069) 
2,036 
(7,343) 
1,261 
(3,631) 
     
Psychotherapy Only     
Adequate 889 
(4,483) 
 
1,348 
(7,702) 
498 
(2,656) 
912 
(3,737) 
Inadequate 94 
(5,890) 
 
1,663 
(11,039) 
859 
(2,604) 
1,893 
(7,194) 
     
Combination     
Adequate 1,002 
(6,255) 
 
1,043 
(6,461) 
869 
(8,649) 
918 
(5,460) 
Inadequate -136 
(4,701) 
 
1,018 
(5,326) 
724 
(4,209) 
2,645 
(6,853) 
     
No Treatment     
Inadequate 138 
(6,365) 
 
-3 
(6,602) 
700 
(4,622) 
826 
(4,926) 
     aStandard deviations are shown in parentheses. 
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Table 3.    Effect of Provider Choice and Treatment Adequacy 
On Medical Cost Offseta 
 
Provider 
Psychiatrist Non-Psychiatrist 
 Immediate Lagged Immediate Lagged 
 Patients with Offset 
All -2,195.24 
[5,620.42] 
(n=763) 
-2,327.91 
[6,084.16] 
(n=728) 
 
-1,519.61 
[4,458.54] 
(n=813) 
-1,584.52 
[4,737.82] 
(n=765) 
Adequate Treatment -2,046.62 
[4,901.64] 
(n=619) 
 
-2,097.73 
[5,009.62] 
(n=616) 
-1,649.00 
[3,489.04] 
(n=157) 
-1,547.30 
[3,406.06] 
(n=158) 
Inadequate Treatment -2,834.10 
[7,999.30] 
(n=144) 
 
-3,593.87 
[10,074.05] 
(n=112) 
-1,488.64 
[4,662.52] 
(n=656) 
-1,594.21 
[5,029.25] 
(n=607) 
     
 Patients without Offset 
All 1,998.49 
[4,841.09] 
(n=2,064) 
 
2,428.20 
[7,720.19] 
(n=2,147) 
1,832.13 
[5,084.16] 
(n=1,900) 
1,919.35 
[4,691.71] 
(n=1,992) 
Adequate Treatment 2,038.84 
[4,975.66] 
(n=1,804) 
 
2,422.24 
[7,726.29] 
(n=1,843) 
2,004.94 
[6,798.22] 
(n=399) 
2,055.76 
[4,374.59] 
(n=409) 
Inadequate Treatment 1,718.56 
[3,773.73] 
(n=260) 
 
2,464.35 
[7,624.37] 
(n=304) 
1,786.19 
[4,522.36] 
(n=1,501) 
1,884.10 
[4,770.91] 
(n=1,583) 
     aThis table excludes individuals who experience no change in cost for the applicable period.  
Standard deviations are shown in brackets. 
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Table 4.    Determinants of Medical Cost-Offset in the 
Immediate and Lagged Periods  
 
Immediate Lagged 
 Coefficient T-Ratio P-Value Coefficient T-Ratio P-Value 
Constant -2147.31 -3.64 <0.01 -3197.41 -4.51 <0.01 
       
Treatment Characteristics       
Non-Physician Provider 2721.50 4.64 <0.01 3012.85 4.19 <0.01 
Adequate Antidepressant Therapy 830.42 1.66 0.10 23.78 0.08 0.94 
Adequate Psychotherapy 51.98 0.25 0.80 410.42 1.78 0.07 
Adequate Combination Therapy -197.35 -0.63 0.53 -382.30 -1.26 0.21 
Inadequate Antidepressant Therapy 696.39 0.97 0.33 36.04 0.10 0.92 
Inadequate Psychotherapy -309.58 -0.92 0.36 946.87 1.59 0.11 
Inadequate Combination Therapy -859.80 -1.26 0.21 353.51 0.40 0.69 
       
Covariates       
Age 9.75 1.33 0.18 15.96 1.91 0.06 
Female Gender -440.51 -2.71 <0.01 -491.18 -1.40 0.02 
Single Episode  Major Depression 38.64 0.09 0.92 823.74 1.37 0.17 
Recurrent Episode Major Depression 454.98 1.26 0.21 1212.41 2.44 0.01 
Dysthymia (Neurotic Depression) 286.79 0.93 0.36 576.21 1.54 0.12 
Brief Reactive Depression 123.66 0.37 0.71 347.81 0.86 0.39 
Prolonged Reactive Depression -10.87 -0.03 0.98 322.33 0.71 0.48 
High Pre-Period Prescription Costs -829.91 -4.33 <0.01 -641.50 -2.73 <0.01 
High Pre-Period Emergency Visits -1500.57 -3.65 <0.00 -1622.35 -3.54 <0.01 
High Pre-Period Physician Visits -1263.55 -7.33 <0.01 -1503.66 -6.71 <0.01 
Number of Anxiolytic Prescriptions 275.13 2.20 0.03 -32.74 -0.37 0.71 
MDC Count 446.62 12.08 <0.01 536.24 11.02 <0.01 
Time -27.55 -0.89 0.37 21.86 0.57 0.57 
Sample Selection Correction  -1748.04 -4.90 <0.01 -1907.78 -4.01 <0.01 
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